BCc1 Nanomedicine Modulates Splenic Cytokine Networks to Enhance Antitumor Innate Immunity in a Murine Breast Cancer Model
Archives of Advances in Biosciences · 01.05.2026
DOI: 10.22037/aab.v16i1.52004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Advances in Biosciences, erschienen am 01.05.2026. Verfasst von Fereshteh Moheb Afzali und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Background and Aim: Breast cancer remains a major cause of cancer mortality in women, and tumor-driven cytokine dysregulation promotes immune escape. This study aimed to define the splenic immunomodulatory activity of BCc1 nanomedicine in 4T1 breast tumor-bearing BALB/c mice by measuring interleukin-12 (IL-12), transforming growth factor-β1 (TGF-β1), and tumor necrosis factor-α (TNF-α), and the (TGF-β1)⁄(IL-12) balance.
Methods
Seventy female mice with palpable tumors received a 24-day regimen of intraperitoneal or oral BCc1, cyclophosphamide, or phosphate-buffered saline (PBS). Splenic cytokines were quantified by ELISA, and the (TGF-β1)⁄(IL-12) ratio was calculated as an index of cytokine polarization.
Results
BCc1 reshaped splenic cytokine patterns in a dose- and route-dependent manner. High-dose intraperitoneal BCc1 produced the strongest effects, markedly reducing and , inducing controlled modulation of , and substantially lowering the ratio. These changes indicate reduced immunoregulatory dominance and a shift toward an antitumor-permissive cytokine milieu. For several cytokine endpoints, high-dose BCc1 showed effects comparable to or greater than cyclophosphamide. Oral BCc1 elicited milder dose-dependent responses, with stronger immunomodulation at the higher oral dose.
Conclusion
BCc1 therefore mediates route- and dose-dependent splenic cytokine remodeling, supporting further evaluation as a multifunctional immunomodulatory nanotherapeutic; cellular phenotyping and functional antitumor assays are required to determine whether these cytokine shifts translate into immune-mediated tumor control Background and Aim: Breast cancer remains a major cause of cancer mortality in women, and tumor-driven cytokine dysregulation promotes immune escape. This study aimed to define the splenic immunomodulatory activity of BCc1 nanomedicine in 4T1 breast tumor-bearing BALB/c mice by measuring interleukin-12 (IL-12), transforming growth factor-β1 (TGF-β1), and tumor necrosis factor-α (TNF-α), and the (TGF-β1)⁄(IL-12) balance.
Methods
Seventy female mice with palpable tumors received a 24-day regimen of intraperitoneal or oral BCc1, cyclophosphamide, or phosphate-buffered saline (PBS). Splenic cytokines were quantified by ELISA, and the (TGF-β1)⁄(IL-12) ratio was calculated as an index of cytokine polarization.
Results
BCc1 reshaped splenic cytokine patterns in a dose- and route-dependent manner. High-dose intraperitoneal BCc1 produced the strongest effects, markedly reducing and , inducing controlled modulation of , and substantially lowering the ratio. These changes indicate reduced immunoregulatory dominance and a shift toward an antitumor-permissive cytokine milieu. For several cytokine endpoints, high-dose BCc1 showed effects comparable to or greater than cyclophosphamide. Oral BCc1 elicited milder dose-dependent responses, with stronger immunomodulation at the higher oral dose.
Conclusion
BCc1 therefore mediates route- and dose-dependent splenic cytokine remodeling, supporting further evaluation as a multifunctional immunomodulatory nanotherapeutic; cellular phenotyping and functional antitumor assays are required to determine whether these cytokine shifts translate into immune-mediated tumor control
Schlagwörter
Zitieren
APA
Afzali, F. M., Heshmati, M., Salimi, A., Kalanaky, S., Fakharzadeh, S., Hafizi, M., Akbari, M. E., Nazaran, M. H., & Hashemi, M. (2026). BCc1 Nanomedicine Modulates Splenic Cytokine Networks to Enhance Antitumor Innate Immunity in a Murine Breast Cancer Model. Archives of Advances in Biosciences. https://doi.org/10.22037/aab.v16i1.52004
Vancouver
Afzali FM, Heshmati M, Salimi A, Kalanaky S, Fakharzadeh S, Hafizi M, et al. BCc1 Nanomedicine Modulates Splenic Cytokine Networks to Enhance Antitumor Innate Immunity in a Murine Breast Cancer Model. Archives of Advances in Biosciences. 2026. doi:10.22037/aab.v16i1.52004
BibTeX
@article{Afzali2026,
author = {Afzali, Fereshteh Moheb and Heshmati, Masoumeh and Salimi, Ali and Kalanaky, Somayeh and Fakharzadeh, Saideh and Hafizi, Maryam and Akbari, Mohammad Esmail and Nazaran, Mohammad Hassan and Hashemi, Mehrdad},
title = {BCc1 Nanomedicine Modulates Splenic Cytokine Networks to Enhance Antitumor Innate Immunity in a Murine Breast Cancer Model},
journal = {Archives of Advances in Biosciences},
year = {2026},
doi = {10.22037/aab.v16i1.52004}
}
EUVIMED